ChemDiv Inc.
http://www.chemdiv.com
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ChemDiv Inc.
Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio
Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.
Deals Shaping The Medical Industry, February 2017
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in January 2017
Collaboration With Torrey Pines Adds To BioMotiv’s Early Momentum
The Cleveland-based biopharma accelerator company signs a $40 million agreement with Torrey Pines Investment to provide early-stage funding and development for innovations emerging from academic research. Previously, BioMotiv raised $46 million from investors to fund its model of accelerating breakthrough discoveries into mid-stage development.
Deals Shaping the Medical Industry (2/2012)
The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Other Names / Subsidiaries
-
- ChemRar Ltd., Chemical Diversity Research Institute., ChemDiv Research Institute
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice